Table 4.

Predictors of cardiovascular disease (CVD) and mortality over 10 years.

Factors	No.	Incident CVD Event HR (95% CI)	p	No.	All-cause Mortality HR (95% CI)	p
Baseline measures
RF positivity	107	1.2 (0.88–1.64)	0.2	96	1.61 (1.13–2.31)^†	0.009
CRP, per 10 mg/l	174	0.99 (0.96–1.03)^†	0.7	147	1.02 (0.98–1.06)^†	0.3
WBC	167	1.04 (0.98–1.10)^†	0.2	142	1.07 (1.00–1.13)^†	0.046
HAQ	174	1.09 (0.85–1.40)	0.5	146	1.35 (1.04–1.75)^†	0.023
Decrease (Δ) in disease measures after 1 year
ΔHAQ	159	0.75 (0.58–0.97)^†	0.029	143	0.90 (0.67–1.19)	0.4
ΔVAS pain, per 10 mm	158	0.98 (0.93–1.03)	0.4	147	0.93 (0.88–0.99)^†	0.015
Measure of disease burden (AUC) up to 2 years
CRP-AUC, per 10 mg/l	148	1.04 (1.00–1.08)^†	0.077	137	1.08 (1.04–1.12)^†	0.000
ESR-AUC, per 10 mm/h	156	1.02 (0.97–1.07)^†	0.4	147	1.06 (1.01–1.10)^†	0.012
DAS28-AUC	154	1.02 (0.95–1.09)	0.7	145	1.09 (1.01–1.17)^†	0.033
HAQ-AUC	153	1.14 (0.99–1.33)^†	0.078	141	1.39 (1.19–1.63)^†	0.000
HAQ at 2 years	160	1.35 (1.05–1.73)^†	0.019	149	1.75 (1.35–2.27)^†	0.000
Therapies the first year
DMARD	134	0.63 (0.44–0.90)^†	0.011	122	0.83 (0.55–1.24)	0.4
MTX	71	0.72 (0.53–0.97)^†	0.033	70	0.95 (0.69–1.31)	0.8
Regular therapies during followup
MTX	93	0.72 (0.53–0.99)^†	0.043	90	0.99 (0.71–1.38)^†	0.9
GC	98	1.65 (1.21–2.26)^†	0.002	87	1.24 (0.90–1.71)	0.19
Biologic agents	21	1.32 (0.83–2.10)^†	0.2	7	0.45 (0.21–0.98)^†	0.045

↵Presented are unadjusted HR for analyses with nonsignificant results. Adjusted HR^† were run if results of the crude analyses showed a p < 0.10. Multivariate models are adjusted for age, sex, smoking status at inclusion, and hypertension, diabetes mellitus, and hyperlipidemia registered throughout the observation period. RF: rheumatoid factor; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; AUC: area under the curve; WBC: white blood (cell) count; DAS28: Disease Activity Score in 28 joints; HAQ: Health Assessment Questionnaire; VAS pain: visual analog scale for pain; DMARD: disease-modifying antirheumatic drugs; MTX: methotrexate; GC: glucocorticoids.